AFT study in American Society of Clinical Oncology's JCOOA shows simple weekly digital symptom check-in improves quality of life and reduces emergency room visits for patients with advanced cancer by bridging communication gaps. News release - https://bit.ly/AFT-39. Study: https://bit.ly/AFT39-JCO
September 15, 2026 at 6:00 AM
AFT study in American Society of Clinical Oncology's JCOOA shows simple weekly digital symptom check-in improves quality of life and reduces emergency room visits for patients with advanced cancer by bridging communication gaps. News release - https://bit.ly/AFT-39. Study: https://bit.ly/AFT39-JCO
🆕 #JCOOA
New options are needed for recurrent/metastatic salivary gland cancer.
In a phase II study, pemetrexed + pembrolizumab showed:
🔹 ORR: 37.5%
🔹 ORR in salivary duct carcinoma: 63.6%
🔹 Median response duration: 15.3 months
Read the article: https://bit.ly/3UYcQnt
New options are needed for recurrent/metastatic salivary gland cancer.
In a phase II study, pemetrexed + pembrolizumab showed:
🔹 ORR: 37.5%
🔹 ORR in salivary duct carcinoma: 63.6%
🔹 Median response duration: 15.3 months
Read the article: https://bit.ly/3UYcQnt
ASCO Publications
ascopubs.org
September 14, 2026 at 1:00 PM
🆕 #JCOOA
New options are needed for recurrent/metastatic salivary gland cancer.
In a phase II study, pemetrexed + pembrolizumab showed:
🔹 ORR: 37.5%
🔹 ORR in salivary duct carcinoma: 63.6%
🔹 Median response duration: 15.3 months
Read the article: https://bit.ly/3UYcQnt
New options are needed for recurrent/metastatic salivary gland cancer.
In a phase II study, pemetrexed + pembrolizumab showed:
🔹 ORR: 37.5%
🔹 ORR in salivary duct carcinoma: 63.6%
🔹 Median response duration: 15.3 months
Read the article: https://bit.ly/3UYcQnt
Patterns of Homologous Repair Deficiency and BRCA1/2 Testing of Ovarian and Breast Cancers: A Real-World Study of Patients in Community Health Settings in the United States ascopubs.org/doi/10.1200/... #JCOOA #OpenAccess
ASCO Publications
ascopubs.org
March 19, 2025 at 1:11 AM
Patterns of Homologous Repair Deficiency and BRCA1/2 Testing of Ovarian and Breast Cancers: A Real-World Study of Patients in Community Health Settings in the United States ascopubs.org/doi/10.1200/... #JCOOA #OpenAccess
“In patients with mRCC, Medicare was associated with significantly better survival outcomes compared with Medicaid/no insurance and having secondary insurance was associated with better PFS compared with primary insurance alone.” ascopubs.org/doi/10.1200/... #JCOOA
ASCO Publications
ascopubs.org
March 14, 2025 at 1:48 AM
“In patients with mRCC, Medicare was associated with significantly better survival outcomes compared with Medicaid/no insurance and having secondary insurance was associated with better PFS compared with primary insurance alone.” ascopubs.org/doi/10.1200/... #JCOOA
#JCOOA: Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid ascopubs.org/doi/10.1200/... #OpenAccess
ASCO Publications
ascopubs.org
March 8, 2025 at 2:18 AM
#JCOOA: Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid ascopubs.org/doi/10.1200/... #OpenAccess
"Our analysis demonstrated OS benefit of the NAC approach in T4 colon adenocarcinoma but not in T3. This study highlights the importance of evaluating the survival benefit of NAC separately for T3 and T4 colon adenocarcinoma in future studies." ascopubs.org/doi/10.1200/... #JCOOA #OpenAccess
Considerations in Neoadjuvant Therapy Implementation in T3 and T4 Colon Cancer | JCO Oncology Advances
PURPOSENeoadjuvant chemotherapy (NAC) is increasingly being considered over standard upfront
surgery followed by adjuvant chemotherapy for locally advanced colon cancer. Studies
have been underpowered...
ascopubs.org
February 26, 2025 at 8:48 PM
"Our analysis demonstrated OS benefit of the NAC approach in T4 colon adenocarcinoma but not in T3. This study highlights the importance of evaluating the survival benefit of NAC separately for T3 and T4 colon adenocarcinoma in future studies." ascopubs.org/doi/10.1200/... #JCOOA #OpenAccess
New from #JCOOA: "Oncologists ... are experiencing higher rates of burnout compared with a decade ago. System-based interventions ... are necessary to maintaining an adequate workforce to provide care for current and future patients..." ascopubs.org/doi/10.1200/...
#JCOOA #JCOJournals #OpenAccess
#JCOOA #JCOJournals #OpenAccess
State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023 | JCO Oncology Advances
PURPOSERecent data suggest that the rate of burnout among oncologists has risen over time.
In addition to the negative effect of burnout on individuals, widespread burnout may
prevent the oncology wor...
ascopubs.org
January 31, 2025 at 9:14 PM
New from #JCOOA: "Oncologists ... are experiencing higher rates of burnout compared with a decade ago. System-based interventions ... are necessary to maintaining an adequate workforce to provide care for current and future patients..." ascopubs.org/doi/10.1200/...
#JCOOA #JCOJournals #OpenAccess
#JCOOA #JCOJournals #OpenAccess
Female med oncs receive significantly lower general payments than male med oncs: Sex-Based Bias in Industry Payments to Medical Oncologists ascopubs.org/doi/10.1200/...
#JCOOA #JCOJournals #OpenAccess
#JCOOA #JCOJournals #OpenAccess
Sex-Based Bias in Industry Payments to Medical Oncologists | JCO Oncology Advances
PURPOSEIndustry payments are common among oncology researchers and can reflect professional
stature and achievement; however, whether such payments differ on the basis of the
sex of the recipient is u...
ascopubs.org
January 16, 2025 at 12:38 PM
Female med oncs receive significantly lower general payments than male med oncs: Sex-Based Bias in Industry Payments to Medical Oncologists ascopubs.org/doi/10.1200/...
#JCOOA #JCOJournals #OpenAccess
#JCOOA #JCOJournals #OpenAccess
New from #JCOOA: Risk Stratification Using Tree-Based Models for Recurrence-Free Survival in Breast Cancer ascopubs.org/doi/10.1200/...
#JCOOA #JCOJournals #OpenAccess #BreastCancer #oncsky
#JCOOA #JCOJournals #OpenAccess #BreastCancer #oncsky
ASCO Publications
ascopubs.org
January 15, 2025 at 3:46 PM
New from #JCOOA: Risk Stratification Using Tree-Based Models for Recurrence-Free Survival in Breast Cancer ascopubs.org/doi/10.1200/...
#JCOOA #JCOJournals #OpenAccess #BreastCancer #oncsky
#JCOOA #JCOJournals #OpenAccess #BreastCancer #oncsky
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors ascopubs.org/doi/10.1200/...
#JCOOA #JCOJournals #oncsky
#JCOOA #JCOJournals #oncsky
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors | JCO Oncology Advances
PURPOSEThis phase Ib study investigated the safety and antitumor activity of BI 836880, a
bispecific nanobody targeting vascular endothelial growth factor and angiopoietin-2,
and ezabenlimab, an anti–...
ascopubs.org
January 13, 2025 at 11:49 PM
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors ascopubs.org/doi/10.1200/...
#JCOOA #JCOJournals #oncsky
#JCOOA #JCOJournals #oncsky
New from #JCOOA: Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma
ascopubs.org/doi/10.1200/...
#openaccess, #JCOJournals, #melanoma, #oncsky, @pamelakunzmd.bsky.social @ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
#openaccess, #JCOJournals, #melanoma, #oncsky, @pamelakunzmd.bsky.social @ascocancer.bsky.social
ASCO Publications
ascopubs.org
January 6, 2025 at 10:19 PM
New from #JCOOA: Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma
ascopubs.org/doi/10.1200/...
#openaccess, #JCOJournals, #melanoma, #oncsky, @pamelakunzmd.bsky.social @ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
#openaccess, #JCOJournals, #melanoma, #oncsky, @pamelakunzmd.bsky.social @ascocancer.bsky.social
Short-Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared with Standard of Care (SAVE): A Randomized Clinical Trial— new today from #JCOOA #oncsky #JCOOncologyAdvances #JCOJournals #gynonc
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
December 4, 2024 at 9:53 PM
Short-Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared with Standard of Care (SAVE): A Randomized Clinical Trial— new today from #JCOOA #oncsky #JCOOncologyAdvances #JCOJournals #gynonc
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
New from #JCOOA Disparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non–Small Cell Lung Cancer: A SEER-Medicare Analysis #oncsky #openaccess #JCOJournals @pamelakunzmd.BlueSky.social
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
December 4, 2024 at 10:22 AM
New from #JCOOA Disparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non–Small Cell Lung Cancer: A SEER-Medicare Analysis #oncsky #openaccess #JCOJournals @pamelakunzmd.BlueSky.social
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
New! Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial #JCOOA #openaccess #oncsky #medsky ascopubs.org/doi/10.1200/...
Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial | JCO Oncology ...
PURPOSEThis retrospective analysis examines the impact of bone metastasis on outcomes in
patients with non–small cell lung cancer (NSCLC) from the CCTG BR.34 trial, which
investigated the combined imm...
ascopubs.org
November 19, 2024 at 3:25 PM
New! Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial #JCOOA #openaccess #oncsky #medsky ascopubs.org/doi/10.1200/...
📣 Have something to report on an ongoing clinical trial? #JCOOA now accepting Trials in Progress articles! Read the first one here:
SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low–Tumor Burden Follicular Lymphoma ascopubs.org/doi/10.1200/...
SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low–Tumor Burden Follicular Lymphoma ascopubs.org/doi/10.1200/...
SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances
ascopubs.org
April 28, 2025 at 3:58 PM
📣 Have something to report on an ongoing clinical trial? #JCOOA now accepting Trials in Progress articles! Read the first one here:
SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low–Tumor Burden Follicular Lymphoma ascopubs.org/doi/10.1200/...
SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low–Tumor Burden Follicular Lymphoma ascopubs.org/doi/10.1200/...
Obama’s JCPOA was NOT “horrible deal”. Trump’s justification for terminating the JCOOA so he could start the Iran War. #LIARTRUMP
June 7, 2026 at 2:23 PM
Obama’s JCPOA was NOT “horrible deal”. Trump’s justification for terminating the JCOOA so he could start the Iran War. #LIARTRUMP
Great news for #cancerresearch! A new ASCO/Friends of Cancer Research study in #JCOOA shows decentralized clinical trial elements are safe to adopt without hurting data quality or increasing patient risk.
Read more: shorturl.at/V7ZsJ
Read more: shorturl.at/V7ZsJ
June 13, 2025 at 10:24 PM
Great news for #cancerresearch! A new ASCO/Friends of Cancer Research study in #JCOOA shows decentralized clinical trial elements are safe to adopt without hurting data quality or increasing patient risk.
Read more: shorturl.at/V7ZsJ
Read more: shorturl.at/V7ZsJ
‼️ #ASCO25 #JCOOA simultaneous publication by O'Neill et al:
Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials. Read the full article: brnw.ch/21wT6uo @pamelakunzmd.bsky.social
Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials. Read the full article: brnw.ch/21wT6uo @pamelakunzmd.bsky.social
June 2, 2025 at 8:06 PM
‼️ #ASCO25 #JCOOA simultaneous publication by O'Neill et al:
Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials. Read the full article: brnw.ch/21wT6uo @pamelakunzmd.bsky.social
Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials. Read the full article: brnw.ch/21wT6uo @pamelakunzmd.bsky.social